Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewSDZ NKT 343
说明： Highly selective human NK1 antagonist
化学名： 1-[[(2-Nitrophenyl)amino]carbonyl]-L-prolyl-N-methyl-3-(2-naphthalenyl)-N-(phenylmethyl)-L-alaninamide
纯度： ≥98% (HPLC)
生物活性 for SDZ NKT 343
SDZ NKT 343 is a highly selective human tachykinin NK1 receptor antagonist (IC50 values are 0.62 and 451 nM for human and rat receptors respectively) that displays > 130-fold selectivity over human NK2 and NK3 receptors. Potently antagonizes SP-induced Ca2+ efflux in vitro and inhibits mechanical hyperalgesia in vivo.
化合物库 for SDZ NKT 343
SDZ NKT 343 is also offered as part of the Tocriscreen 2.0 Max. 了解 Tocris 化合物库的更多信息。
技术数据 for SDZ NKT 343
| 分子量 | 579.65 |
| 公式 | C33H33N5O5 |
| 储存 | Store at +4°C |
| 纯度 | ≥98% (HPLC) |
| CAS Number | 180046-99-5 |
| PubChem ID | 9851211 |
| InChI Key | PCVSIMQAFWRUEC-JDXGNMNLSA-N |
| Smiles | O=C(NC3=C([N+]([O-])=O)C=CC=C3)N1[C@H]([C@@](N[C@H]([C@@](N(C)CC4=CC=CC=C4)=O)CC2=CC=C(C=CC=C5)C5=C2)=O)CCC1 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶解性数据 for SDZ NKT 343
| 溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
|---|---|---|---|
| 溶解性 | |||
| DMSO | 57.97 | 100 | |
| ethanol | 57.97 | 100 |
制备储备液 for SDZ NKT 343
以下数据基于产品分子量 579.65。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| 浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.73 mL | 8.63 mL | 17.25 mL |
| 5 mM | 0.35 mL | 1.73 mL | 3.45 mL |
| 10 mM | 0.17 mL | 0.86 mL | 1.73 mL |
| 50 mM | 0.03 mL | 0.17 mL | 0.35 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
产品说明书 for SDZ NKT 343
参考文献 for SDZ NKT 343
参考文献是支持产品生物活性的出版物。
Walpole et al (1998) Comparative, general pharmacology of SDZ NKT 343, a novel, selective NK1 receptor antagonist. Br.J.Pharmacol. 124 83 PMID: 9630347
Walpole et al (1998) 2-Nitrophenylcarbamoyl-(S)-prolyl-(S)-3-(2-naphthyl)alanyl-N-benzyl-N-methylamide (SDZ NKT 343), a potent human NK1 tachykinin receptor antagonist with good oral analgesic activity in chronic pain models. J.Med.Chem. 41 3159 PMID: 9703462
Campbell et al (1998) Selective neurokinin-1 receptor antagonists are anti-hyperalgesic in a model of neuropathic pain in the guinea-pig. Neuroscience. 87 527 PMID: 9758219
If you know of a relevant reference for SDZ NKT 343, please let us know.
按标靶查看相关产品
按产品操作查看相关产品
关键词: SDZ NKT 343, SDZ NKT 343 supplier, selective, human, NK1, antagonists, Tachykinin, Receptors, Neurokinin, SDZNKT343, Receptor, 2394, Tocris Bioscience
篇 SDZ NKT 343 的引用文献
引用文献是使用了 Tocris 产品的出版物。
目前没有 SDZ NKT 343 的引用文献。 您是否知道使用了 Tocris SDZ NKT 343 的优秀论文？ 请告知我们.
SDZ NKT 343 的评论
目前没有该产品的评论。 Be the first to review SDZ NKT 343 and earn rewards!
Have you used SDZ NKT 343?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Peptides Involved in Appetite Modulation Scientific Review
Written by Sonia Tucci, Lynsay Kobelis and Tim Kirkham, this review provides a synopsis of the increasing number of peptides that have been implicated in appetite regulation and energy homeostasis; putative roles of the major peptides are outlined and compounds available from Tocris are listed.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.